Secondary Prevention & Cardiac Rehabilitation Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital, London.

Slides:



Advertisements
Similar presentations
PRIMIS Third National Conference Tuesday 1 April 2003 Birmingham HIP for CHD Jane Matthews Practice Nurse Dr. Dai Evans PRIMIS Regional Clinical Adviser.
Advertisements

THE ROLE OF THE CARDIAC NURSE PRACTITIONER
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Population Health Gain in Primary Care Dr Hilary Guite FFPH MRCGP Consultant Public Health Medicine Public Health England
Coronary Revascularisation in Patients With Diabetes Mellitus Dr Rod Stables The Cardiothoracic Centre Liverpool UK.
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
,000 20,00030,000 Rest Normal 50% Lesion 90% 75% Work of the Heart (double product) Coronary Blood Flow.
Journal Club Alcohol and Health: Current Evidence January–February 2007.
Research with clinical populations: Cardiac rehabilitation Shawn N Fraser University of Alberta.
The concept of Diabetes & CV risk: A lifetime risk challenge Diabetes & CV Risk: Routine practice versus guidelines Eberhard Standl, MD Professor of Medicine.
Promoting Excellence in Cardiovascular Disease Prevention and Rehabilitation The BACPR Standards and Core Components for Cardiovascular Prevention and.
Cardiovascular Rehabilitation and Secondary Prevention – Why is it so important?
Orlando, Florida – October 7, 2011 Cardiac Rehab: Improving Outcomes One Step at a Time Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
Management of Stable Angina SIGN 96
Heart Failure Programs Europe and Belgium Sandra Martin Clinical Nurse Specialist UZ Leuven, Belgium.
Modern Management of Cholesterol in the High-Risk Patient.
Cardiac Rehabilitation – The Evidence Base & Implications for Practice Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Heart Disease! UCLH Trust Members 2010 Dr Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Monitoring CAC and IMT: A useful clinical tool? Cardiology Service Walter Reed Army Medical Center Walter Reed Army Health Care System NO CONFLICTS TO.
Cardiac Rehabilitation (CR) in General Practice Karen Kjær Larsen MD, PhD student Department of General Practice School of Public Health Aarhus University.
BACR Standards: A Useful Tool? Jennifer George / Michelle Bull SWL Cardiac and Stroke Network.
Silent Ischemia STABLE CAD
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Review of an article Not all Angiotension-Converting Enzyme (ACE) inhibitors are Equal: Focus on Ramipril and Perindopril DiNicolantonio J, Lavie C, O’Keefe.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
R1 강민혜 / prof. 전숙. Introduction Patients with type 2 diabetes have a greatly increased risk of cardiovascular events. The morbidity and mortality related.
SECONDARY PREVENTION IN HEART DISEASE CATHY QUICK AUBURN UNIVERSITY/AUBURN MONTGOMERY EBP III.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Management Strategies for Post-Intervention in Patients with CAD VBWG.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Medical Therapy With Versus Without Revascularization.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Women and Cardiovascular Disease
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
The Importance of Adequately Powered Studies
Recent Breakthroughs in Cardiovascular Outcomes Trials in T2DM
Revascularization in Patients With Left Ventricular Dysfunction:
PCI related in-hospital mortality based on race and gender in the USA
The Anglo Scandinavian Cardiac Outcomes Trial
AIM HIGH Niacin plus Statin to prevent vascular events
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Section 9: Continuum of care: Summary and timeline
Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit  Barry A. Franklin, PhD  Mayo.
Preventive Angioplasty in Myocardial Infarction Trial
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Role of Stenting in Acute MI: PAMI Stent Pilot Trial
Goals & Guidelines A summary of international guidelines for CHD
SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.
Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.
Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Cardiovascular Epidemiology and Epidemiological Modelling
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Secondary Prevention & Cardiac Rehabilitation Malcolm Walker Consultant Cardiologist UCLH & the Heart Hospital, London

Malcolm Walker NO CONFLICT OF INTEREST TO DECLARE

COURAGE Trial

When the PCI is over, what else could there possibly be left to do?

J Am Col Cardiology. 2008; 52: Patients with significant coronary stenoses are at increased risk of future cardiac events. However, in the absence of acute coronary syndrome or recent MI and residual ischemia, elective PCI has not been shown to improve prognosis.

Reviews of Exercise Based Rehabilitation Reviews No. of RCTs No. of Patients Meta- analysi s Relative Reduction in Total Mortality Exercise or Exercise plus CR Oldridge 1988 O’Connor 1989 Bobbio YesYesYes 24% (8 to 37%) 20% (4 to 34%) 32% (14 to 47%) Cochrane Review: Joliffe et al patients after MI or Revascularisation Exercise only: 27% fall in all cause mortality; 31% fall in cardiac mortality Exercise + : 13% fall in all cause mortality; 26% fall in cardiac mortality

2004 Metanalysis 2004 Metanalysis 48 RCTs, n= RCTs, n= 8940 Patients hospitalised for CHD Patients hospitalised for CHD Conclusion: 20% reduction in all cause mortality 24% in cardiovascular mortality Conclusion: 20% reduction in all cause mortality 24% in cardiovascular mortality Cardiac Rehabilitation - the Statin era Taylor, R.S. et.al. Am J Med 2004

Walther et.al. Eur J Cardiovasc Prev Rehabil. 2008; 15: Hambrecht group – Event-free survival in exercise versus PCI groups at 24 months

hs CRP levels at Baseline & 24 Months p = p = ns Walther et.al. Eur J Cardiovasc Prev Rehabil. 2008; 15:

How might exercise improve CAD outlook Improved associated cardiovascular risk factors –Improved physical fitness –Weight –Diabetes –HDL levels –Adherence to improved diet –Reduced smoking –Improved compliance with medication –Markers of inflammation: e.g. hs CRP –Endothelial function

patients post PCI 213 patients post PCI Non-randomised: 133 received CR, 80 no CR Non-randomised: 133 received CR, 80 no CR Mean follow-up 4.5yr Mean follow-up 4.5yr Results: Results: Readmission for CAD event 45% CR vs 75% no CR Readmission for CAD event 45% CR vs 75% no CR Revascularisation 7% CR vs 17% no CR Revascularisation 7% CR vs 17% no CR Total health care cost: 4862 Eu/pt vs 5498 Eu/pt Total health care cost: 4862 Eu/pt vs 5498 Eu/pt 15/12 MACE 24% CR vs 42% no CR P< /12 MACE 24% CR vs 42% no CR P<0.005 Cardiac Rehabilitation (CR) - after PCI Dendale P. et.al. Acta Cardiol 2008

Core components of CR

NACR Annual Statistical Report: week Medication Record

NACR Annual Statistical Report: month outcome (NSF Targets)

NACR Annual Statistical Report: Reasons for referral to CR

NACR Annual Statistical Report:2008 Percentage Eligible Patients Who Receive CR in England

Barriers to CR Speed of throughput –Tertiary centre syndrome Not my responsibility –The nurses will do it –It’s primary care’s job Patient reluctance the “Andy Capp syndrome”

Well Mr Capp, just have the PCI

Overcoming the Barriers to CR Local CR programmes have to be –Accessible –Flexible –Responsive –Visible –Provide CR to a level known to improve prognosis Cardiologists have to take responsibility for the complete “package” of care… or assume the role of cardiac interventional radiologists

Can we see a time when all PCI patients from CR? Dream on